PDR001

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Well-differentiated Non-functional NET of Thoracic Origin

Conditions

Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Trial Timeline

Feb 14, 2017 → May 13, 2020

NCT ID

NCT02955069

About PDR001

PDR001 is a phase 2 stage product being developed by Novartis for Well-differentiated Non-functional NET of Thoracic Origin. The current trial status is completed. This product is registered under clinical trial identifier NCT02955069. Target conditions include Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin.

What happened to similar drugs?

1 of 1 similar drugs in Well-differentiated Non-functional NET of Thoracic Origin were approved

Approved (1) Terminated (0) Active (0)

✅sunitinibPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04058756	Phase 1	Active	Oct 30, 2019	Apr 30, 2030	Advanced Solid Tumors
NCT02955069	Phase 2	Completed	Feb 14, 2017	May 13, 2020	Well-differentiated Non-functional NET of Thoracic Origin
NCT02678260	Phase 1	Completed	Feb 19, 2016	Sep 1, 2017	Advanced Malignancies
NCT02404441	Phase 1/2	Completed	Apr 27, 2015	Jul 21, 2020	Melanoma

Competing Products

2 competing products in Well-differentiated Non-functional NET of Thoracic Origin

See all competitors

Product	Company	Stage	Hype Score
sunitinib	Pfizer	Approved	43
INCMGA00012 + Palbociclib	Incyte	Phase 2	36